138 related articles for article (PubMed ID: 38649657)
21. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy.
Chhun S; Jullien V; Rey E; Dulac O; Chiron C; Pons G
Epilepsia; 2009 May; 50(5):1150-7. PubMed ID: 19175400
[TBL] [Abstract][Full Text] [Related]
22. Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema.
Wang Y; Jomphe C; Marier JF; Martin P
J Clin Pharmacol; 2021 Apr; 61(4):555-564. PubMed ID: 33091166
[TBL] [Abstract][Full Text] [Related]
23. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
[TBL] [Abstract][Full Text] [Related]
24. Two Cases of Cardiovascular Adverse Events Following Subcutaneous Vosoritide Injection in Early Infancy.
Nishioka A; Adachi N; Tanaka H; Oda Y
Cureus; 2024 May; 16(5):e59695. PubMed ID: 38841012
[TBL] [Abstract][Full Text] [Related]
25. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
Gandhi Y; Passarell JA; Roy A; Murthy B
J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
[TBL] [Abstract][Full Text] [Related]
26. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
27. A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children.
Schipani A; Pertinez H; Mlota R; Molyneux E; Lopez N; Dzinjalamala FK; van Oosterhout JJ; Ward SA; Khoo S; Davies G
Br J Clin Pharmacol; 2016 Apr; 81(4):679-87. PubMed ID: 26613187
[TBL] [Abstract][Full Text] [Related]
28. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
Wrobel W; Pach E; Ben-Skowronek I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
[TBL] [Abstract][Full Text] [Related]
29. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
30. Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Aruldhas BW; Hoglund RM; Ranjalkar J; Tarning J; Mathew SK; Verghese VP; Bose A; Mathew BS
Br J Clin Pharmacol; 2019 Mar; 85(3):644-654. PubMed ID: 30588647
[TBL] [Abstract][Full Text] [Related]
31. Population Pharmacokinetic Model to Optimize Cefotaxime Dosing Regimen in Critically Ill Children.
Béranger A; Oualha M; Urien S; Genuini M; Renolleau S; Aboura R; Hirt D; Heilbronner C; Toubiana J; Tréluyer JM; Benaboud S
Clin Pharmacokinet; 2018 Jul; 57(7):867-875. PubMed ID: 28980166
[TBL] [Abstract][Full Text] [Related]
32. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
33. Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
Nikanjam M; Kabamba D; Cressey TR; Burger D; Aweeka FT; Acosta EP; Spector SA; Capparelli EV
Antimicrob Agents Chemother; 2012 Oct; 56(10):5374-80. PubMed ID: 22869579
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.
Gastine S; Lehrnbecher T; Müller C; Farowski F; Bader P; Ullmann-Moskovits J; Cornely OA; Groll AH; Hempel G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038273
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age.
Girgis IG; Nandy P; Nye JS; Ford L; Mohanty S; Wang S; Ochalski S; Eerdekens M; Cox E
Epilepsia; 2010 Oct; 51(10):1954-62. PubMed ID: 20880232
[TBL] [Abstract][Full Text] [Related]
36. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
Juul RV; Rasmussen MH; Agersø H; Overgaard RV
Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamics results of a long-acting C-type natriuretic peptide prodrug, TransCon CNP.
Breinholt VM; Mygind PH; Christoffersen ED; Zhang Y; Ota S; Will Charlton R; Viuff D
Br J Clin Pharmacol; 2022 Nov; 88(11):4763-4772. PubMed ID: 35481707
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
McLeay SC; Green B; Treem W; Thyssen A; Mannaert E; Kimko H
Clin Pharmacokinet; 2014 Oct; 53(10):943-57. PubMed ID: 25168707
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Zheng B; Yu XQ; Greth W; Robbie GJ
Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
